Defined regions of the CDR2-1ike region of the T cell antigen CD4 that are implicated in the binding of the surface glycoprotein (gpl20) of human immunodeficiency virus type 1 (HIV-1) to CD4 + T lymphocytes have been engineered in place of antigenic site 1 of Sabin type 1 poliovirus. The antigenic properties of the recovered chimeric virus particles were investigated using monoclonal antibodies (MAbs) and polyclonal serum to CD4. None of the MAbs tested neutralized the chimeras, presumably because they are directed against conformational determinants on the V1 domain of CD4.
Introduction
The antigenic and three-dimensional structures of poliovirus have been well characterized (Minor, 1990; Hogle et al., 1985) . This information, together with the availability of infectious cDNA clones of the virus (Racaniello & Baltimore, 1981) , has allowed the construction and recovery of antigen chimeras, in which a well defined antigenic site is replaced with an amino acid sequence derived from an alternative source (Rose & Evans, 1991) . Intertypic chimeras, constructed by the exchange of residues corresponding to antigenic site 1 of serotypes 1 and 2 or 3, display dual antigenicity and composite immunogenicity (Burke et al., 1988; Martin et al., 1988; Murray etal., 1988b; Minor etal., 1990 Minor etal., , 1991 . Antigenic site 1 occupies the region separating the fl-B and fl-C strands of VP1 (residues 92 to 102 in Sabin 1) and forms a relatively free standing loop that projects at the pentameric apex of the icosahedral virus particle (Hogle et al., 1985) . This region of the virus capsid has also been replaced with known or predicted epitopes from other pathogens, whilst retaining virus viability Kitson et al., 1991; Jenkins et al., 1990; Altmeyer et al., 1991 ; Dedieu et al., 1992; Lemon et al., 1992) . A proportion of such chimeric viruses present the foreign epitope in an antigenically or immunogenically relevant conformation. To date, known or predicted neutralization epitopes from a variety of pathogens have been used to replace antigenic site 1. We report here the construction and characterization of poliovirus chimeras that present sequences derived from the cell surface antigen CD4.
The CD4 antigen was originally defined as a phenotypic marker for a subset of helper T lymphocytes (Reinherz et al., 1979) where it is involved in the interaction of the T cell receptor and major histocompatibility complex (MHC) class II molecules. However, the demonstration that CD4 is the cellular receptor for the human immunodeficiency viruses HIV-1 and HIV-2 led to its extensive structural and functional analysis (Maddon et al., 1986) . A variety of techniques were used to locate the principal residues of CD4 that are involved in the interaction with the external envelope glycoprotein (gp 120) ofHlV (Arthos et al., 1989; Landau et al., 1988; Peterson & Seed, 1988; Brodsky et al., 1990) . These occupy residues 35 to 50 of the first domain of the Ig-like molecule, analogous in location to the second complementarity-determining region (CDR2) of an GTG  GAT  AAC  TCA  GCT  TCC  ACC  AAG  AAT  AAG  CAT  AAG  CTA  TTT   CAC  CTA  TTG  AGT  GCA  AGG  TGG  TTC  TTA  TTC  CTA  TTC  GAT Nucleotide and amino acid sequences of antigenic site 1 of Sabin 1 and the antigen chimeras S1/CD4/I, S1/CD4/3 and S1/CD4/3.1. Residues in bold indicate sequences derived from the CDR2-1ike region of CD4. The numbering of residues in bold relates to the amino acid sequence of the mature CD4 protein and to other residues corresponds to VP1 of Sabin 1. Nucleotides in large type correspond to the synthetic oligonucleotides ligated with the cassette vectors pCAS1 or PCAS7, those in small type encode residues in Sabin 1. Nucleotides underlined represent the ApaI or BamHI sites used to screen recombinants. The upper (coding) strand alone is shown for the variant pS1/CD4/3.5 from which the virus S1/CD4/3.1 was recovered.
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immunoglobulin light chain. The recent determination of the three-dimensional structure of domains 1 and 2 of CD4 (Ryu et al., 1990; Wang et al., 1990) have shown this region to be a highly prominent surface loop consisting of the C'C" fl strands. The extensive information available on the CDR2-1ike region of CD4 makes it suitable for investigating the detailed molecular presentation of a defined loop in a foreign location. Since this region of CD4 is also strongly implicated in gpl20 binding, we were interested in determining whether chimeric viruses expressing suitable sequences from CD4 could interact with gpl20, and therefore possibly define the minimal functional region required for binding to the virus attachment protein of HIV. The results obtained demonstrate that poliovirus can present CD4-derived sequences in an antigenically and immunogenically relevant conformation, but that in this example such sequences cannot confer an additional tropism on the virus particle.
Methods
Construction and recovery of poliovirus-CD4 antigen chimeras. The poliovirns cassette vectors (pCAS1 or pCAS7) that allow the efficient modification of the region of the eDNA encoding antigenic site 1 have been described previously Evans & Almond, 1991 ) . Both vectors encode a similar Sabin type 1 backbone, the difference being that pCAS7 contains a number of modifications facilitating the screening and recovery of chimeric viruses. Recombinant cDNAs were generated following published protocols (Evans & Almond, 1991) . Briefly, complementary pairs of oligonucleotides ( Fig. 1) encoding the desired sequences were ligated into SalI/DraI-cut pCAS 1 or pCAS7. In the case of S1/CD4/3, two pairs of oligonucleotides were used to specify the CD4 sequence, overlapping at the unique BamH[ site within the insert. Recombinants were screened by restriction analysis and the correct modification of the cDNA was confirmed by DNA sequencing. Correct recombinant plasmids were linearized with NaeI (for pCAS1-based constructs) or MluI (pCAST) and used as templates for the in vitro synthesis of RNA transcripts using T7 RNA polymerase (Van der Weft et al., 1986; Evans & Almond, 1991) . A subcontinent monolayer of Ohio HeLa (O. HeLa) fibroblast cells were transfected using DEAE~ztextran with half of the in vitro transcription reaction mixture and incubated at 34 °C in an atmosphere containing 5 % CO s. The recovery of viable virus was monitored by the appearance of a c.p.e. and the sequence of antigenic site 1 in the chimeric virus was determined either by direct sequencing of the viral RNA (Rico Hesse et al., 1987) or by the cloning of PCR fragments into pEMBL18+ followed by dsDNA sequencing. Growth characteristics of recombinant viruses were determined as described previously (Jenkins et al., 1990) .
Antibodies and reagents. Sheep polyclonal antisera to poliovirus type l and monoclonal antibodies (MAbs) to antigenic sites 1, 2 and 3 of type ! poliovirus have been described previously (Minor et aL, 1986 (Minor et aL, , 1987 , as has MAb 303 which binds to the poliovirus receptor and On: Tue, 11 Dec 2018 18:25:15 blocks virus infection . CD4 MAbs Leu 3a and NU-TH/1 were a generous gift from Dr Q. Sattentau. CD4 MAbs Q4120, L120.3, JAH 7.3Fll, RFT4, JAH 7.2G4 and 12.16.A2.F9 were obtained from the MRC AIDS Directed Programme Reagent Project, reference numbers ADP318, ADP359, ADP337, ADP302, ADP336 and ADP356 respectively, as were CD4 sheep polyclonal antiserum $91 (ADP405), alkaline phosphatase-conjugated sheep polyclonal antipeptide serum to the C terminus of gp120 D7324-AP (ADP451), the HeLa T4 + cell line (ADP019), recombinant baculovirus-expressed soluble CD4 (sCD4; ADP609) and recombinant CHO cell-or baculovirus-expressed gpl20 (rgpl20; ADP604 or ADP607). MAb 1577 and env3 are monoclonal and polyclonal sera respectively raised against the poliovirus antigen chimera Sl/env/3 expressing an 18-residue sequence from HIV-1 gp41 . CHO cells (160E7) expressing gpl60 were kindly provided by Dr P. Stephens. HeLa vCD4 F43C and HeLa vCD4 G47A cell lines were generated by electroporation of HeLa cells with a pEE6-derived vector (Stephens & Cockett, 1989) containing a cDNA encoding a variant CD4 molecule. Stably transfected cells were selected using neomycin at 1 mg/ml and cloned following separation using Dynabeads M-450 CD4 (Dynal).
Neutralization assay. The neutralization of virus by type 1 sites 1-, 2-and 3-specific MAbs, a type 1 polyclonal antiserum, or MAbs generated against the chimera S1/CD4/1 were measured by standard microtitre methods (Minor, 1985 ) using a constant challenge (100 TCIDs0) of virus. Both the chimera and Sabin type 1 were incubated alone or with the appropriate dilution of antisera for 2 h at 34 °C prior to the addition of 1 x 104 O. HeLa cells. Residual virus titre was determined after 5 days by staining with crystal violet.
Production of polyelonal sera and MA bs to polio virus antigen chimeras. Rabbits were immunized intradermally with 0'5 ml of tissue culture fluid containing the relevant antigen chimera (approximately l0 s TCIDs0 ) in complete Freund's adjuvant. Two subsequent doses prepared in incomplete Freund's adjuvant were administered subcutaneously at monthly intervals. A panel of murine MAbs were generated against the chimera designated S1/CD4/1 using established techniques (Ferguson et al., 1984) . Hybridoma supernatants were screened in a single radial immunodiffusion assay against the immunizing chimera and Sabin type 1, and were considered to be specific for the introduced epitope when they reacted with the chimera but not Sabin type 1. Six such antibodies were generated and were designated 1683 , 1684 , 1685 , 1686 , 1687 and 1692 . IgG class 16-series MAbs (1684 , 1685 , 1686 , 1687 and 1692 were purified using Protein G-Sepharose 4 Fast Flow (Pharmacia) according to the manufacturer's instructions and the protein concentration was determined using the Pierce BCA Assay Reagent, prior to storage at -20 °C.
Cell binding assays. HeLa cells expressing CD4 (HeLa T4 +) or variant CD4 (vCD4) molecules bearing single amino substitution of either Phe 43 for Cys (HeLa vCD4 F43C) or Gly 47 for Ala (HeLa vCD4 G47A) were seeded at a density of 5 x 10 ~ cells per well into 24-well plates. Confluent monolayers were incubated with 100 gl antisera at 10 pg/ml in 1% fetal calf serum/Dulbecco's MEM/0.02 % NaN 3 for 2 h at 4 °C. Bound antibodies were detected by 100 p.1 125I-or 35S-labelled anti-species antibody (1×105 counts per ml in 1% FCS/Dulbecco's MEM; Amersham). After washing, cells were lysed with 200 ~tl 4 M-NaOH/1% Empigen, transferred to scintillation vials and counts were recorded in an LKB Multigamma or LKB 1214 Rackbeta counters. Immunofluorescence assays were carried out using a similar protocol, substituting fluorescein isothiocyanate-conjugated goat anti-mouse antibody (SeraLabs) for the detection agent.
Generation of escape mutants. MAb neutralization-resistant (escape) mutants of S1/CD4/1 and S1/CD4/3 were generated using the MAbs 1683 and 1687 according to published methods (Ferguson et al., 1984) . After generating small working stocks, the recovered mutants were sequenced across the antigenic site 1 as described above.
Poliovirus antigen chimera CD4 regions 971
ELISA. Antisera raised against the chimeras were tested for their ability to recognize solid phase sCD4 by ELISA. Recombinant baculovirus-expressed sCD4 was bound directly to the solid phase (Falcon ProBind) overnight in binding buffer (30 mM-sodium bicarbonate, pH 8-6). Non-specific binding was blocked with 2 % Marvel in TBS (144 mM-NaC1, 25 mM-Tris-HCl pH 7.5). Antisera (100 p.1), diluted in TMT/SS (2 % Marvel, 0.5 % Tween-20, 20 % sheep serum in TBS), were allowed to bind for 2 h at room temperature. Bound antibodies were detected by binding 100 pl alkaline phosphatase (AP)-conjugated anti-species antibody diluted 1 : 1000 in TMT/SS for 1 h at room temperature. After washing, bound AP antibody was detected using DEA buffer and phosphatase substrate (Kirkegaard and Perry Laboratories), and the absorbance was recorded at 405 nm. The ability of antisera generated against the chimeras to block the interaction of gpl20 with sCD4 was assessed essentially according to Moore et al. (1989) . MAb L120.3 was used to capture sCD4 to a plate (Falcon ProBind) prior to the addition of the test antisera. Recombinant gp 120 was allowed to bind, and detected with D7324-AP. AMPAK ELISA (Novo Biolaboratories) substrate and amplifier were used according to the manufacturer's instructions, and the absorbance was read at 492 nm.
Blocking HIV-1 infection or HIV-l-induced syncytium formation. The ability of MAbs or rabbit sera raised against S1/CD4/I or S1/CD4/3 to block HIV infection of CD4 + T cells was determined as previously reported . MOLT4 cells (1001al at 2 x 10 ~ cells/ml) were incubated with 10 pl of sample antisera or MAb for 2 h at 37 °C and subsequently infected with a 100 TCIDs0 dose of NY-5/LAI in a volume of 50 pl. Virus infection was scored (3 days post-infection) by examining for the presence of syncytia, and the reciprocal dilution of sera capable of blocking syncytium formation was recorded. The antibodies were also tested for their ability to block cell~zell fusion. Briefly, M8166 cells (100 pl at 2 x 105 cells/ml) were incubated with 10 lal of the sample antisera or MAb for 1 h at 37 °C followed by the addition of 100lal LAI-infected H9 cells (2 x 104 cells/ml). The presence or absence of syncytia at 37 °C was scored 24 h post-cultivation.
Results

Construction and characterization of poliovirus-CD4 chimeras
Based upon our previous experience in generating viable poliovirus antigen chimeras expressing defined sequences from foreign proteins, we searched the CDR2-1ike region of CD4 for potential sequences for insertion in place of antigenic site 1. Oligonucleotides encoding CD4 residues 39 to 53 and 32 to 56 were annealed and ligated into either pCAS1 or pCAS7 to generate recombinant plasmids pS1/CD4/1.1 and pS1/CD4/3.8 respectively (Fig.  1 ). An additional recombinant plasmid (pS1/CD4/3.5) containing a fortuitous mutation in the CD4 nucleotide sequence was also identified during screening. Recombinant plasmids were linearized with MluI or NaeI and used as templates for the in vitro generation of run-off RNA using bacteriophage T7 RNA polymerase, and a c.p.e, was observed 3 to 5 days after transfection of sub-confluent O. HeLa cell monolayers with the RNA. The recovered viruses were designated S1/CD4/1, S1/CD4/3 and S1/CD4/3.1 respectively, and sequenced through a region of approximately 300 bp spanning the modified antigenic site to confirm the presence of the CD4-derived sequences. The point mutation observed in pS1/CD4/3.5 resulted in a Lys to Arg substitution at residue 46 (Lys46Arg) in the CD4-derived sequence of S1/CD4/3.1 (Fig. 1) . Growth characteristics of S 1/CD4/1, S 1/CD4/3 and the parental Sabin type 1 were determined by examining single-step growth curves. Both chimeras exhibited impaired replication, typified by a lengthened latent phase and a reduction of the final titre, of up to 90 % in the case of S1/CD4/3 (Fig. 2) . However, plaques formed by the chimeras were indistinguished from those of Sabin type 1 (data not shown). The chimeras were neutralized by MAbs to poliovirus type 1 antigenic sites 2 and 3 and by type 1 polyclonal antiserum, but were not neutralized by a site 1-specific MAb (data not shown). The infectivity of susceptible cells was blocked by MAb 303 that is specific for the cellular receptor for poliovirus, and blocks infection of permissive cells (data not shown). The CD4-1ike antigenic characteristics of the chimeric viruses were determined by neutralization assay using MAbs and polyclonal antisera to sCD4. None of the MAbs specific for the first immunoglobulin-like domain of CD4 that were tested (Leu 3a, NU-TH/1, RFT4, JAH 7.2G4) neutralized the poliovirus-CD4 chimeras or Sabin 1 (data not shown). In contrast, sheep polyclonal antiserum to recombinant CD4 ($91) neutralized chimeras S1/CD4/1, S1/CD4/3 and S1/CD4/3.1 at a titre of >1:1000, >1:16000 and >1:16000 respectively (Table 1) .
Immunogenicity of S1/ CD4/1
To determine whether the chimeric viruses have antigenic characteristics similar to CD4, a panel of murine MAbs to S 1/CD4/1 were generated. Hybridoma supernatants were screened in antigen blocking assays (Minor, 1985) against radiolabelled Sabin 1 and S1/CD4/1, and were considered to be specific for the introduced CD4 epitope if they reacted solely with the chimera, and not with the parental Sabin 1 virus. The isotype of the MAbs was determined and shown to be IgG2a for MAbs 1684, 1685, 1687 and 1692, whereas MAb 1686 was IgG2b and MAb 1683 an IgM. As expected, all the MAbs in the panel neutralized the immunogen S1/CD4/1 ( Table 1) . The panel were also tested for the MAbs' ability to neutralize S1/CD4/3, and the related chimera S1/CD4/3.1. With the exception of MAb 1686, which did not neutralize S1/CD4/3.1, both chimeras were neutralized by all the MAbs generated against S 1/CD4/1 (Table 1) .
Selection and characterization of neutralization escape mutants
To investigate further the precise recognition of the CD4-derived sequence, two MAbs were chosen to select neutralization-resistant escape mutants of S1/CD4/1 and S1/CD4/3. MAbs 1683 and 1687 were selected as representing two distinct classes of antibodies; MAb 1683 is an IgM and failed to react with solid-phase sCD4, whereas MAb 1687 is an IgG2a which binds solid-phase sCD4 (see below). A total of 15 mutants, eight derived from S1/CD4/1 and seven from S1/CD4/3, were sequenced and all contained amino acid substitutions within the window that was sequenced (corresponding to residues 50 to 121 of VP1). These were restricted to the CD4-derived sequence introduced into antigenic site 1 (Fig. 3) . Mutant viruses that were representative of a particular amino acid change were tested for neutralization by the remaining panel of 16-series MAbs (Table 2) , and by $91.
Recognition of CD4 by MAbs
To determine the structural relationships between the CDR2-1ike region presented in the poliovirus chimeras and the native CD4 molecule, MAbs and rabbit polyclonal antisera that were generated against the chimeras were assessed for their ability to recognize CD4. The IgG class MAbs (1684 MAbs ( , 1685 MAbs ( , 1686 MAbs ( , 1687 MAbs ( and 1692 were purified on a Sepharose-Protein G column and the reactivity with sCD4 bound to the solid phase was tested. Half-maximal binding levels of MAbs 1686, 1687, 1684 and 1692 were observed between 0-12 and 2"5 gg/ml (Fig. 4) , whereas MAb 1685 showed only very low levels of binding which did not saturate at 10 gg/ml. Although not purified, MAb 1683 only displayed levels of sCD4 binding comparable to the negative control MAb 1577 (data not shown). The control MAb Q4120 (CD4 V1 domain) bound less well than MAbs 1684, 1686 and 1687, presumably refecting the conformational nature of its epitope. In similar experiments, polyclonal rabbit antisera to S1/CD4/1 and S1/CD4/3 both recognized sCD4 in the solid phase (data not shown).
To determine whether the reactivity of the MAbs or polyclonal sera with sCD4 bound to the solid phase (and therefore at least partially denatured) differed from that with CD4 in its native conformation, the antisera were also tested for their ability to bind to HeLa cells transfected with CD4, using either a 1~5I-or fluorescein isothiocyanate-labelled anti-species conjugate for detection. Three cell lines were selected for these experi- ments: HeLa T4 + that express an unmodified CD4 molecule, H e L a vCD4 F43C and HeLa vCD4 G47A. The HeLa vCD4 cell lines express considerably higher levels of CD4 than HeLa T4 ÷, and contain single amino acid substitutions within the CDR2-1ike region of CD4. Control MAbs raised against the V1 (JAH 7.3F11), V2 (12.16.A2.Fg) and V4 (L120.3) domains of CD4 all exhibited significant levels of binding to cell surfaceexpressed CD4 on all three cell lines, whereas only background levels of binding were observed for M A b 1577 (Fig. 5a ). Of the 16-series MAbs, only MAb 1686 bound to the three CD4-expressing cell lines. No significant binding was observed of either the control MAbs or the 16-series MAbs to HeLa cells that did not express CD4 or vCD4 molecules (data not shown). The anti-CD4 MAbs and MAb 1686 that were binding to cell surface CD4 (or vCD4) could be detected by immunofluorescence, whereas no binding was observed with MAb 1577, or with any of the tested MAbs to HeLa cells lacking CD4 (data not shown). Further radiolabelled binding studies using aSS-anti-species conjugate for detection demonstrated that rabbit antisera to S1/CD4/1 (R24, R25, R26) and S 1 / C D 4 / 3 . 1 (R208.3) also bound to HeLa T4 + cells, as did positive control rabbit serum CBL34, whereas control rabbit antiserum to an unrelated poliovirus chimera (S1/env/3) exhibited only background levels of binding (Fig. 5b) .
Interaction with gpl20 and blocking of CD4-gpl20 interactions
The interaction of the poliovirus-CD4 chimeras with gpl20 was assessed in vitro by ELISA, and by poliovirus plaque-reduction assay using rgpl20 at saturating concentrations, in the same manner as an antibody. In neither assay could binding of chimeric virus of rgpl20 be demonstrated (data not shown). To test whether the oligomeric structure of gp120 could affect the binding of Binding of polyclonal rabbit antiserum raised against S1/CD4/1 (R24, R25 and R26) or Sl/CD4/3 (R208.3) to HeLa T4 + cells. Bound antibodies were detected using 35S-labelled anti-species antibody and their radioactivity was counted by scintillation. CBL34 and env3 are polyclonal rabbit antisera raised against sCD4 and the unrelated poliovirus chimera S1/env/3 respectively, bkg, Background c.p.m.
poliovirus-CD4 chimeras the interaction of radiolabelled S1/CD4/1 and S1/CD4/3 with gpl60-expressing C H O cells (160E7) was determined. No differences in binding to 160E7 cells or untransfected C H O cells could be observed (data not shown). In parallel studies, MAbs or rabbit antisera raised against S1/CD4/1 or S1/CD4/3 were shown not to affect the interaction of sCD4 and rgpl20 in vitro, or to affect either the infection of M8166 cells by HIV-1, or the syncytium formation of HIV-1-infected H9 cells and uninfected M8166 cells (data not shown).
Discussion
As part of a wider study into the antigenicity of the poliovirus particle and the exploitation of poliovirus as an epitope presentation vector, three antigen chimeras of poliovirus presenting defined regions of the V1 domain of CD4 have been constructed and characterized. As expected from previous studies on poliovirus antigen chimeras (Burke et al., 1988; Martin et al., 1988 ; Murray et al., 1988b; Minor et al., 1990 Minor et al., , 1991 Evans et al., 1989; Kitson et al., 1991 ; Jenkins et al., 1990; Altmeyer et al., 1991; Rose & Evans, 1991; Dedieu et al., 1992; Lemon et al., 1992) , the modifications of antigenic site 1 had only localized effects upon the antigenicity of the virus particle. This accords with the current understanding of the processing, assembly and structure of the virus particle (Hellen & Wimmer, 1992a, b; Hogle et al., 1985) . Significant alterations to the antigenicity of sites 2 or 3 are likely to require more severe alterations to VPt that are likely to render the particle non-infectious due to defects in processing, assembly or interaction with the cellular receptor. In addition to the chimeras behaving serologically as poliovirus, replacement of antigenic site 1 did not appear to alter the requirement for the cellular receptor for poliovirus during infection. Although presenting sequences derived from the cellular receptor for HIV, the poliovirus CD4 chimeras did not bind to rgpl20, or display an additional tropism for gpl60-expressing cells (see below). Both S1/CD4/1 and S1/CD4/3 exhibited impaired growth characteristics in comparison with Sabin 1. Since the yield of S 1/CD4/3 in particular is markedly reduced, growth of the chimeras appears to be related to the length of the introduced epitope, although we and others have observed that this is not always the case. Investigation of the antigenic properties of the CD4-derived sequences of S1/CD4/1 and S1/CD4/3 was restricted by the availability of MAbs with suitable properties. The majority of antibodies raised against the V1 domain of CD4 recognize discontinuous epitopes (Peterson & Seed, 1988; Brodsky et al., 1990) , and it was therefore not surprising that the chimeras S1/CD4/1 and S1/CD4/3, which present linear CD4 peptides, were not neutralized by anti-CD4 MAbs. However, polyclonal sheep antiserum ($91) raised against sCD4 did recognize the chimeras, implying that they exhibited at least some of the antigenic properties of CD4.
Neutralization of S1/CD4/3 by the MAbs raised against S1/CD4/1 suggests that presentation of the recognized epitope(s) is similar on both chimeras. The CD4-derived residues presented by S1/CD4/1 are not situated centrally within the S1/CD4/3 insert ( Fig. 1 and  3 ). This implies that the amino acids contributing to the MAb recognition sites within residues 39 to 53 have an intrinsic structure which is not significantly affected by the length of the flanking sequences that anchor them to the core of VP1. The pattern of neutralization-resistant variants selected with MAbs 1683 and 1687 further emphasizes the similarity of the structure of S 1/CD4/1 and S1/CD4/3 (see below). Only one of the MAbs, 1686, did not neutralize the related chimera $1/CD4/3.1, suggesting that either Lys46 is a critical contact residue for MAb 1686, or that the Lys46Arg substitution significantly alters the conformation of the epitope recognized by this MAb.
Four out of six MAbs (1684, 1686, 1687 and 1692) raised against S1/CD4/1 were shown to recognize solidphase sCD4 by ELISA. MAb 1685 displayed only very weak binding to solid-phase sCD4, whereas MAb 1683 did not bind. Although the screening procedure used to select chimera-specific MAbs ensures that at least part of the epitope that is recognized lies within the region engineered into the chimera, it does not exclude the possibility that a MAb specific for a particular chimera may react with a discontinuous epitope, only part of which occupies the modified antigenic site 1. To test whether this was the case with MAb 1683, a total of seven neutralization-resistant escape mutants were selected for with the MAb and were sequenced through the introduced epitope (Fig. 3) . All contained substitutions of CD4 amino acid residues 47, 48, 49 or 50 which, although not excluding the involvement of other regions of the capsid, strongly suggests that MAb 1683 recognition primarily involves sequences within the modified antigenic site 1.
Neutralization-resistant variants of S1/CD4/1 and S1/CD4/3 were also selected with MAb 1687. The pattern of substitutions observed was similar to that seen for MAb 1683, although mutations were only observed in the CD4-derived amino acid residues 48 and 49. The antigenicity of representative mutants was tested by neutralization assay using the six MAbs generated during this study and $91. The failure to neutralize S1/CD4/1-derived mutants bearing substitutions of CD4 amino acid residues 47 and 48 (Table 2) suggests that $91 has a relatively monospecific reactivity with CD4 sequences between amino acids 39 and 53. There was very little difference in the recognition of S1/CD4/1-or S1/CD4/3-derived variants containing substitutions of the same amino acid by the MAbs tested. The inhibition of neutralization by the 16-series MAbs of S 1/CD4/1-or S1/CD4/3-derived viruses bearing substitutions of CD4 amino acid residues 48 or 49 ( Table 2 ) suggests either that these amino acids are common to the epitopes recognized by the MAbs, or that changes at these positions result in a conformational change to the CD4-derived loop that is sufficient to prevent MAb binding.
Comparison of the cross-neutralization pattern observed allows the MAbs to be grouped into representative subclasses. MAbs 1683 and 1686 have to be grouped individually because of their failure to react with sCD4 and S1/CD4/3.1, respectively. The remaining 16-series MAbs are all affected by substitutions of CD4 amino acid residues 47, 48 and 49 and so can tentatively be grouped together. However, it is likely that this grouping is artificially restricted by the small number of neutralization-resistant variants selected and screened. Although MAb 1685 appears by cross-neutralization to be a member of this group, its very weak binding to solidphase sCD4 and failure to bind cell surface-expressed CD4 suggest that there may be subtle differences in the recognition of the CD4-derived sequences by this MAb. It should also be noted that similar antibody groupings could be made on the basis of class and/or isotype. Only one of the 16-series MAbs (MAb 1686) recognized CD4 expressed at the surface of HeLa cells, or the vCD4 molecules expressed by HeLa vCD4 F43C or HeLa vCD4 G47A. The recognition of HeLa vCD4 G47A is consistent with the observation that this MAb was the only one to neutralize the S1/CD4/1-derived escape mutant 13222 bearing a G47E substitution ( Table 2 ), implying that the epitope that was recognized by this MAb is unique among the panel tested. This conclusion is further supported by the inability of MAb 1686 to neutralize the related chimera S1/CD4/3.1 bearing the Lys46Arg mutation (Table 1) , which was neutralized by all other members of the 16-series MAb panel at high titre. Although MAb 1686 bound to native CD4, it did not block the interaction ofgpl20 with CD4 in the assays used. These results suggest that MAb 1686 may not have a high enough affinity to block the gpl20-CD4 interaction, which has been reported to have an association constant of at least 10~/M (Lasky et al., 1987; Moore & Jarrett, 1988) .
Since the chimeras constructed during this study expressed a region of CD4 strongly implicated in the interaction with the external envelope glycoprotein of HIV-1, their ability to bind to gpl20 was tested. Neutralization of poliovirus via antibodies directed against antigenic site 1 is likely to be due to direct or indirect disruption of the interaction between the virus and its cellular receptor (Altmeyer et al., 1991) . However, in plaque reduction assays rgpl20 did not affect the titre of the input virus, even in the presence of a sheep antipeptide polyclonal antiserum (D7324) added to crosslink the glycoprotein (data not shown). Furthermore, no differences could be seen in the binding of radiolabelled Sabin 1, S1/CD4/1 or S1/CD4/3 to captured gpl20. It was therefore unsurprising that neither of the chimeras could infect or bind to CHO cells expressing anchored gp 160. Therefore, although these poliovirus-CD4 chimeras express a region of CD4 implicated in gpl20 binding, and shown when presented as a larger peptide to block the gpl20-CD4 interaction (Ghetie et al., 1991) , the precise CD4 amino acid sequence presented or the conformation adopted by the CD4 peptide were not sufficient to confer an additional tropism to these chimeras.
In conclusion, the Sabin 1 strain ofpoliovirus has been used as an epitope expression vector to present defined sequences from the CDR2-1ike region of CD4, the cellular receptor for HIV. Polyclonal sera and MAbs raised against one of the two chimeras were used to characterize the epitope expression. Results suggested that the precise conformation of the foreign epitope on S1/CD4/1 and S1/CD4/3 was very similar. The polyclonal rabbit antisera and one of the MAbs recognized CD4 in its native conformation when expressed on the surface of stably transfected cells. These results represent the first use of poliovirus to present epitopes other than those from a pathogen, and suggest that this system may have more general application in the generation of MAbs raised against defined sequences of interest.
